Repligen (NASDAQ:RGEN) Stock Price Expected to Rise, Royal Bank of Canada Analyst Says

Repligen (NASDAQ:RGEN) had its price target hoisted by equities research analysts at Royal Bank of Canada from $203.00 to $205.00 in a research note issued on Friday,Benzinga reports. The firm currently has an “outperform” rating on the biotechnology company’s stock. Royal Bank of Canada’s price target would indicate a potential upside of 30.55% from the stock’s current price.

A number of other analysts have also weighed in on the stock. Canaccord Genuity Group raised their price objective on shares of Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a research note on Friday. TD Cowen began coverage on shares of Repligen in a research note on Monday, February 10th. They set a “buy” rating and a $200.00 price objective for the company. StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a research note on Friday, January 3rd. JPMorgan Chase & Co. raised their price objective on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday. Finally, HC Wainwright restated a “buy” rating and set a $180.00 price objective on shares of Repligen in a research note on Friday. Six investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $183.36.

Repligen Stock Down 3.5 %

NASDAQ RGEN traded down $5.65 during trading hours on Friday, reaching $157.02. 239,254 shares of the company’s stock traded hands, compared to its average volume of 592,207. Repligen has a 52-week low of $113.50 and a 52-week high of $203.13. The firm has a market cap of $8.80 billion, a PE ratio of -424.14, a PEG ratio of 4.23 and a beta of 0.99. The firm has a 50-day simple moving average of $155.17 and a 200 day simple moving average of $148.81. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The company had revenue of $167.55 million during the quarter, compared to analysts’ expectations of $167.58 million. Sell-side analysts anticipate that Repligen will post 1.54 EPS for the current fiscal year.

Hedge Funds Weigh In On Repligen

A number of institutional investors and hedge funds have recently made changes to their positions in the business. GTS Securities LLC purchased a new position in shares of Repligen in the fourth quarter worth approximately $264,000. Gordian Capital Singapore Pte Ltd purchased a new position in Repligen during the fourth quarter valued at approximately $259,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Repligen by 12.8% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 235,343 shares of the biotechnology company’s stock valued at $33,875,000 after purchasing an additional 26,733 shares in the last quarter. Two Sigma Advisers LP lifted its holdings in Repligen by 6.7% during the fourth quarter. Two Sigma Advisers LP now owns 134,800 shares of the biotechnology company’s stock valued at $19,403,000 after purchasing an additional 8,500 shares in the last quarter. Finally, Raiffeisen Bank International AG purchased a new position in Repligen during the fourth quarter valued at approximately $29,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.